Cargando…

Clinical trials of disease-modifying agents in pediatric MS: Opportunities, challenges, and recommendations from the IPMSSG

OBJECTIVE: The impetus for this consensus discussion was to recommend clinical trial designs that can deliver high-quality data for effective therapies for pediatric patients, in a reasonable timeframe, with a key focus on short- and long-term safety. METHODS: The International Pediatric Multiple Sc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Waubant, Emmanuelle, Banwell, Brenda, Wassmer, Evangeline, Sormani, Maria-Pia, Amato, Maria-Pia, Hintzen, Rogier, Krupp, Lauren, Rostásy, Kevin, Tenembaum, Silvia, Chitnis, Tanuja
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6556085/ https://www.ncbi.nlm.nih.gov/pubmed/31043474 http://dx.doi.org/10.1212/WNL.0000000000007572

Ejemplares similares

Current international trends in the treatment of multiple sclerosis in children—Impact of the COVID-19 pandemic
por: Sandesjö, Fredrik, et al.
Publicado: (2021)

Preventing Multiple Sclerosis: The Pediatric Perspective
por: Hardy, Duriel, et al.
Publicado: (2022)

Consistent control of disease activity with fingolimod versus IFN β-1a in paediatric-onset multiple sclerosis: further insights from PARADIGMS
por: Deiva, Kumaran, et al.
Publicado: (2020)

Effect of fingolimod on health-related quality of life in paediatric patients with multiple sclerosis: results from the phase 3 PARADIGMS Study
por: Krupp, Lauren, et al.
Publicado: (2022)

Effect of fingolimod on MRI outcomes in patients with paediatric-onset multiple sclerosis: results from the phase 3 PARADIGMS study
por: Arnold, Douglas L, et al.
Publicado: (2020)

Recommendations for observational studies of comorbidity in multiple sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2016)

Clinical features of neuromyelitis optica in children: US Network of Pediatric MS Centers report
por: Chitnis, Tanuja, et al.
Publicado: (2016)

Distinct effects of obesity and puberty on risk and age at onset of pediatric MS
por: Chitnis, Tanuja, et al.
Publicado: (2016)

The challenge of comorbidity in clinical trials for multiple sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2016)

Do the current MS clinical course descriptors need to change and if so how? A survey of the MS community
por: Thompson, Alan J, et al.
Publicado: (2023)

Plasma neurofilament light chain in children with relapsing MS receiving teriflunomide or placebo: A post hoc analysis of the randomized TERIKIDS trial
por: Kuhle, Jens, et al.
Publicado: (2023)

Effect of vitamin D on MS activity by disease-modifying therapy class
por: Rotstein, Dalia L., et al.
Publicado: (2015)

Predicting long-term disability outcomes in patients with MS treated with teriflunomide in TEMSO
por: Sormani, Maria Pia, et al.
Publicado: (2017)

Increased leptin and A-FABP levels in relapsing and progressive forms of MS
por: Messina, Silvia, et al.
Publicado: (2013)

Lung involvement correlates with disability in MS patients with COVID-19 pneumonia
por: Immovilli, Paolo, et al.
Publicado: (2022)

An Italian programme for COVID-19 infection in multiple sclerosis
por: Sormani, Maria Pia
Publicado: (2020)

Brief International Cognitive Assessment for MS (BICAMS): international standards for validation
por: Benedict, Ralph HB, et al.
Publicado: (2012)

Family Perspectives on Clinical Research for Pediatric Multiple Sclerosis: Enhancing Equity
por: Mandel, Leslie A, et al.
Publicado: (2021)

Heterogeneity in association of remote herpesvirus infections and pediatric MS
por: Nourbakhsh, Bardia, et al.
Publicado: (2018)

Blood neurofilament light as a potential endpoint in Phase 2 studies in MS
por: Sormani, Maria Pia, et al.
Publicado: (2019)

A framework for measurement and harmonization of pediatric multiple sclerosis etiologic research studies: The Pediatric MS Tool-Kit
por: Magalhaes, Sandra, et al.
Publicado: (2018)

The COVID-19 pandemic and the use of MS disease-modifying therapies
por: Giovannoni, Gavin, et al.
Publicado: (2020)

MRI activity in MS and completed pregnancy: Data from a tertiary academic center
por: Houtchens, Maria, et al.
Publicado: (2020)

Elevated EBNA-1 IgG in MS is associated with genetic MS risk variants
por: Kreft, Karim L., et al.
Publicado: (2017)

Environmental and genetic risk factors for MS: an integrated review
por: Waubant, Emmanuelle, et al.
Publicado: (2019)

Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis
por: De Stefano, Nicola, et al.
Publicado: (2016)

Comparison of dimethyl fumarate and interferon outcomes in an MS cohort
por: Sattarnezhad, Neda, et al.
Publicado: (2022)

Identification of MS-specific serum miRNAs in an international multicenter study
por: Regev, Keren, et al.
Publicado: (2018)

Different MRI patterns in MS worsening after stopping fingolimod
por: Lapucci, Caterina, et al.
Publicado: (2019)

International consensus diagnostic criteria for neuromyelitis optica spectrum disorders
por: Wingerchuk, Dean M., et al.
Publicado: (2015)

Quantitative MRI analysis in children with multiple sclerosis: a multicenter feasibility pilot study
por: Chitnis, Tanuja, et al.
Publicado: (2013)

The Role of CD4 T Cells in the Pathogenesis of Multiple Sclerosis
por: Chitnis, Tanuja
Publicado: (2007)

COVID-19 severity among patients with multiple sclerosis treated with cladribine: A systematic review and meta-analysis
por: Albanese, Angela, et al.
Publicado: (2022)

Cross-sectional study of smoking exposure: no differential effect on OCT metrics in a cohort of MS patients
por: Rosso, Mattia, et al.
Publicado: (2019)

Biomarkers Indicative of Blood-Brain Barrier Disruption in Multiple Sclerosis
por: Waubant, Emmanuelle
Publicado: (2006)

The Effect of Disease-Modifying Drugs on Brain Atrophy in Relapsing-Remitting Multiple Sclerosis: A Meta-Analysis
por: Branger, Pierre, et al.
Publicado: (2016)

Interplay Between Endocrine Disruptors and Immunity: Implications for Diseases of Autoreactive Etiology
por: Popescu, Maria, et al.
Publicado: (2021)

Optical coherence tomography and visual evoked potentials in pediatric MS
por: Waldman, Amy T., et al.
Publicado: (2017)

Researching COVID-19 in progressive MS requires a globally coordinated, multi-disciplinary and multi-stakeholder approach—perspectives from the International Progressive MS Alliance
por: Zaratin, Paola, et al.
Publicado: (2022)

Assessing heterogeneity of treatment effect in multiple sclerosis trials
por: Sormani, Maria Pia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_htiisij9og5mjfkrbnro2bkboi